Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically or cytologically proven ovarian epithelial cancer, fallopian tube
cancer, or primary peritoneal cancer

- Progressive disease as defined by RECIST criteria and/or CA-125 criteria

- Advanced disease

- Previously treated with 1-2 prior platinum-containing regimen(s)

- Prior hormonal therapy does not count towards the prior treatment

- Responded to the most recent prior platinum-containing regimen(s) OR no evidence
of progression during platinum-containing therapy as documented by RECIST
criteria or CA-125 criteria (for patients with no macroscopic residual disease
after surgery who are not evaluable by CA-125)

- Disease relapse 6-12 months after completion of the most recent platinum-containing
therapy

- Patients who received two prior lines of treatment must have had ≥ 6 months
between their first and second lines of treatment

- Patients with disease progression, as defined by CA-125 criteria alone, within 6
months after completion of their last treatment are eligible provided study
treatment commences > 6 months after the last prior treatment

- Patients with disease progression, as defined by GCIG guidelines, within 12
months after completion of their last treatment are eligible provided study
treatment commences ≤ 14 months after the last prior treatment

- Measurable disease by RECIST criteria and/or CA-125 criteria

- Measurable lesions are defined as those that can be accurately measured in at
least one dimension (longest diameter to be recorded) as ≥ 20 mm by conventional
techniques (physical examination, CT scan, x-ray, or MRI) or as ≥ 10 mm by
spiral CT scan

- Patients with evaluable disease by CA-125 criteria are eligible provided CA-125
is ≥ 2 times upper limit of normal (ULN) within 2 weeks prior to initiating
study treatment

- Disease is not considered measurable if patient received prior mouse antibodies
or if there has been medical and/or surgical interference with the peritoneum or
pleura (e.g., paracentesis) within the past 28 days

- Ascites requiring therapeutic drainage allowed only if there is measurable disease by
RECIST criteria

- Ascites that do not require therapeutic drainage allowed even if disease is
evaluable by CA-125 criteria alone

PATIENT CHARACTERISTICS:

- WHO performance status 0-2

- Hemoglobin ≥ 10.0 g/dL

- WBC ≥ 3.0 x 10^9/L

- Neutrophil count ≥ 1.5 x 10^9/L

- Platelet count ≥ 100 x 10^9/L

- Bilirubin ≤ 30 μmol/L

- ALT and/or AST ≤ 2.5 times ULN (≤ 5 times ULN if due to tumor involvement of liver)

- EDTA/DTPA clearance ≥ 50 mL/min (uncorrected value)

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception for 4 weeks prior to, during, and
for 6 months after completion of study treatment

- No known hepatitis B, hepatitis C, or HIV positivity

- No non-malignant systemic disease, including active uncontrolled infection, that
would make the patient a high medical risk

- No other current malignancies, except adequately treated cone-biopsied in situ
carcinoma of the cervix or basal cell or squamous cell carcinoma of the skin

- Patients who have undergone potentially curative therapy for a prior malignancy
are eligible provided there is no evidence of disease for ≥ 5 years and the
patient is deemed to be at low risk for recurrence

- No intolerance to carboplatin (with a dose of ≥ AUC 5), as defined by any of the
following:

- Neutropenia or thrombocytopenia causing dose delay of > 4 days on more than 2
occasions

- Grade III or IV hypersensitivity reaction (not controlled by a desensitization
regimen)

- Hospitalization for confirmed febrile neutropenia (fever ≥ 38°C)

- Requirement for platelet transfusion

- No other condition that, in the investigator's opinion, would not make the patient a
good candidate for this study

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- Recovered from prior therapy (alopecia, grade 1 neuropathy, and certain grade 1
toxicities allowed)

- More than 28 days since prior maintenance therapy (e.g., erlotinib or bevacizumab)

- More than 4 weeks since prior radiotherapy, endocrine therapy, immunotherapy,
chemotherapy, biological therapy, or investigational agents

- More than 4 weeks since prior major thoracic and/or abdominal surgery and recovered

- No other concurrent anti-cancer therapy, including radiotherapy or investigational
drugs